We are an integrated product development company primarily focused on
therapeutics for pain utilizing our proprietary drug delivery technologies. Our
lead product candidate is Fentanyl TAIFUN®, a fentanyl formulation specifically
designed to be delivered with our TAIFUN® Multi-Dose Inhaler.
We are developingFentanyl TAIFUN® as a rapid-acting inhaled opioid analgesic for treatment of
break-through cancer pain. In June 2007, we entered into an exclusive license
and development agreement with Janssen Pharmaceutica N.V. with respect to the
continuing development and commercialization of Fentanyl TAIFUN®. We believe,
based upon the results of our clinical trials to date, that our Fentanyl TAIFUN®
product candidate, if approved by regulatory agencies, will deliver much faster
onset of pain relief from break-through cancer pain at lower dosages than other
non-injectable products currently indicated for break-through cancer pain.
Break-through cancer-related pain has a severe impact on a patient's quality
of life and can occur even if the individual is taking chronic pain medication
on a regular basis. Break-through pain is a common component of chronic pain and
is characterized by its rapid onset, intensity and relatively short duration.
These intermittent flare-ups of intense pain "break-through" the effect of
chronic pain medication. We believe currently available therapeutics targeted at
break-through cancer pain are inadequate because of their higher dosage of
fentanyl and comparatively longer time to onset.
Company Details
- Employees
- 17
- Founded
- -
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- akelapharma.com
- Keywords
- Artemisa Direct.
Akela Pharma, Inc. Questions
Akela Pharma, Inc.'s website is akelapharma.com
Akela Pharma, Inc.'s LinkedIn profile is https://www.linkedin.com/company/akela-pharma-inc.
Akela Pharma, Inc. has
17 employees.
View email and phone details for 17
employees at Akela Pharma, Inc..
Akela Pharma, Inc.'s industry is
Pharmaceutical Manufacturing
Akela Pharma, Inc.'s top competitors are
Compugroup Medical Polska,
Oval Medical Technologies Ltd,
Accubiotech Co., Ltd.,
Artemisa Direct,
+watt S.r.l.,
Genemedicine,
Cura Diagnostics Inc.,
Simpliteca.com,
Akela | Creative Health Nutrition,
Ko-Med Clinical Centers.
Akela Pharma, Inc.'s categories are Pharmaceutical Manufacturing
Akela Pharma, Inc.'s founding year is 1996
